The Effective Use of Anti-obesity Medications.

Anti-obesity medications Combination therapy GLP-1 receptor agonists Obesity pharmacotherapy Off-label prescribing Treatment of obesity

Journal

Gastroenterology clinics of North America
ISSN: 1558-1942
Titre abrégé: Gastroenterol Clin North Am
Pays: United States
ID NLM: 8706257

Informations de publication

Date de publication:
12 2023
Historique:
medline: 6 11 2023
pubmed: 3 11 2023
entrez: 2 11 2023
Statut: ppublish

Résumé

Obesity is a heterogeneous disease and there is wide patient-to-patient variability in response to all anti-obesity treatments including lifestyle modifications, anti-obesity medications (AOMs), devices, and bariatric surgery. To effectively treat obesity, practitioners must be knowledgeable about all of these treatment modalities including on-label and off-label AOMs. Care should be individualized to the patient taking into consideration their unique challenges with weight loss, their goals, the presence of comorbidities, medication contraindications, and drug-drug interactions. There is currently no way to know which AOM will be most effective for a patient without trial and error; therefore, prescribe AOMs in sequence and consider combination therapy for optimal results. This article reviews the efficacy, safety, prescribing information, and other considerations for all of the currently available AOMs.

Identifiants

pubmed: 37919019
pii: S0889-8553(23)00081-X
doi: 10.1016/j.gtc.2023.08.003
pii:
doi:

Substances chimiques

Anti-Obesity Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

661-680

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure S.H. Schmitz reports no disclosures. L.J. Aronne reports receiving consulting fees from/and serving on advisory boards for Allurion, Altimmune, Atria, Gelesis, Jamieson Wellness, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novo Nordisk, Pfizer, Optum, Eli Lilly, Senda Biosciences and Versanis; receiving research funding from Allurion, AstraZeneca, United Kingdom, Gelesis, Janssen Pharmaceuticals, United States, Novo Nordisk and Eli Lilly; having equity interests in Allurion, ERX Pharmaceuticals, Gelesis, Intellihealth, Jamieson Wellness and Myos Corp; and serving on a board of directors for ERX Pharmaceuticals, Intellihealth and Jamieson Wellness.

Auteurs

Sarah H Schmitz (SH)

Division of Endocrinology, Diabetes & Metabolism, New York-Presbyterian Hospital/ Weill Cornell Medical College, Comprehensive Weight Control Center, 1305 York Avenue, 4th Floor, New York, NY 10021, USA. Electronic address: hls9007@med.cornell.edu.

Louis J Aronne (LJ)

Division of Endocrinology, Diabetes & Metabolism, New York-Presbyterian Hospital/ Weill Cornell Medical College, Comprehensive Weight Control Center, 1305 York Avenue, 4th Floor, New York, NY 10021, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH